Temazepam
Temazepam. Intermediate-acting benzodiazepine targeted at sleep onset + maintenance. Glucuronide metabolism (no CYP) → DDI-light. Less hangover… Oral half-life 9.9 h.
Intermediate-acting benzodiazepine targeted at sleep onset + maintenance. Glucuronide metabolism (no CYP) → DDI-light. Less hangover than long-acting benzodiazepines. Schedule IV; chronic use carries dependence + cognitive risk in elderly.
PK: F 0.96 IS THE VOLUME OF DISTRIBUTION IN LITRES PER KILOGRAM. The cited abstract states "volume of distribution, 0.961 kg-1", and the registry used that one number TWICE — correctly scaled to a 67 L volume, and again as a bioavailability. A new shape: the same source figure entered into two different fields. No temazepam absolute bioavailability exists in PubMed at all, since no intravenous study has ever been done, so F is pinned to 1 and the volume is flagged apparent. The half-life of 11 h also matches two contaminants — a cimetidine INTERACTION arm at 11.4 h and the lower bound of an END-STAGE RENAL DISEASE range — while the paper own value of 9.9 h is the only one consistent with the clearance it also reports. A genuine published absorption rate replaces the unsourced one, taken from the NIGHT-TIME arm because this is a bedtime hypnotic; the morning arm differs, so this drug is measurably chronopharmacokinetic. EFFECT SHOWS CLOCKWISE HYSTERESIS — acute tolerance — so effect falls faster than plasma and no effect compartment should be added.
Pharmacokinetics
- Oral — t½ 9.9 h · F 100% · ka 1.31 h⁻¹ · Vd 67 L
Sources: PMID:2207300, PMID:2891534, PMID:2858279